Status:
COMPLETED
Testing the Cognitive Facilitation Effect by Dietary Supplementation of MelaGene+ Drink
Lead Sponsor:
TCI Co., Ltd.
Conditions:
Cognitive Change
Eligibility:
All Genders
20-65 years
Phase:
NA
Brief Summary
To assess the efficacy of MelaGene+ on cognitive performance
Eligibility Criteria
Inclusion
- 20 to 65-year-old males or females
Exclusion
- Participants are breastfeeding, pregnant or planning to become pregnant during the test (self-report)
- Participants with heart, liver, kidney, endocrine and other major organic diseases (self-reported)
- Participants take drugs for a long time (self-report)
- Participants with mental illness or have undergone brain surgery
- Participants still can not clearly see words with 12pt on computer after corrected vision
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2023
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT05988593
Start Date
September 1 2022
End Date
May 31 2023
Last Update
August 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University
Taichung, Taiwan